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Abstract Patients with elevated and/or rising pros-
tate-speciﬁc antigen (PSA), minor lower urinary tract
symptoms (LUTS), and no evidence for prostate
cancer on (multiple) extended prostate biopsies are a
regularly encountered problem in urological practice.
Even now, patients are seen with no objective
explanation of this persistent elevated and/or rising
PSA. So far, many strategic proposals have been
elaborated and published to deal with this speciﬁc
population including the use of different PSA deri-
vates; applying different biopsy schemes—strate-
gies—biopsy target imaging; diagnostic use of
prostate cancer genes; and many more. In this review,
we propose a new algorithm in which an urodynamic
evaluation should be included since bladder outlet
obstruction (BOO) can be expected. Once BOO is
conﬁrmed, a transurethral resection of the prostate
(TURP) can be offered to these patients. This
procedure will result in subjective and biochemical
improvement and allows extensive histological exam-
ination. Current literature was reviewed with regard
to this speciﬁc population. This research was per-
formed using the commercially available Medline
online search tools and applying the following search
terms: ‘‘diagnostic TURP’’; ‘‘elevated PSA’’; and
‘‘prostate biopsy’’. Furthermore, subsequent reference
search was executed on retrieved articles.
Keywords Benign prostatic hyperplasia (BPH) 
Bladder outlet obstruction (BOO)  Prostate
cancer  Transurethral resection of the prostate
(TURP)  Elevated prostate-speciﬁc antigen (PSA)
Introduction
Twenty-ﬁve percent of men over 50 years old have
lower urinary tract symptoms (LUTS). LUTS may be
caused by benign prostatic hyperplasia (BPH), one of
the most common diseases among ageing men and
the second most common cause of surgery in men
over 60 years old [1]. Another condition that might
be accompanying LUTS could be prostate cancer
(PCa), which has become the most common cancer in
men in several developed countries, especially in
Western populations and particularly among the
black population of the United States.
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(PSA) has been introduced in clinical practice [2],
many patients are referred to an urologist because of
elevated and/or rising PSA levels. To ﬁnd the cause
of these elevated and/or rising PSA levels, often
extended prostate biopsies are taken. If cancer cells
are discovered in the biopsies, therapy is usually
straightforward. If, however, prostate biopsies are
negative for cancer cells, numberless diagnostic
strategies have been put forward. When PSA levels
remain high or rise even more, new extended prostate
biopsies are usually taken, eventually with different
methods. When PSA levels keep on rising and when
extended prostate biopsies remain negative in this
group of patients, uncertainty will grow for patients,
as well as for general practitioners and last but not
least for urologists. More speciﬁcally, this will be the
case if the patient suffers only minor LUTS. We have
previously shown that this group of patients (patients
with elevated/and or rising PSA levels, minor LUTS
and no signs of prostate cancer) are likely to have
bladder outlet obstruction (BOO) on pressure ﬂow-
metry according to Abram–Grifﬁths deﬁnition [3, 4].
Despite minor to no LUTS, transurethral resection of
prostate (TURP) is a therapeutic option that can be
offered to patients resulting in (super)normalisation
of PSA levels, symptomatic beneﬁt, and improve-
ment of the quality of life. Additionally, this
technique allows extended histological examination,
which will reveal in few cases prostate cancer that
can be aggressive and need further treatment. Since
patients with elevated and/or rising PSA, minor
LUTS, and (multiple) negative extended prostate
biopsies can be expected to have BOO, we elaborated
a new algorithm in which we propose to consider
urodynamic evaluation as well as the possibility of
performing a TURP in this group of patients.
What are urologists doing today with patients
presenting with elevated and/or rising PSA levels,
minor LUTS, and no signs of prostate cancer on
(multiple) extended prostate biopsies?
Strategies related to PSA evaluation
If PSA is elevated and/or rising in a patient with
minor LUTS, no signs of prostate cancer on digital
rectal examination and/or transrectal ultrasound
(TRUS), and eventually on extended prostate biop-
sies, different PSA derivates have been proposed. A
ﬁrst PSA derivative that can be used is age-related
PSA levels [5]. However, the use of age-speciﬁc PSA
cut-off values can result in missing up to 60% of
cancers in men older than 60 years of age [6]. Borer
concluded that age-speciﬁc PSA references did not
safely eliminate the need for prostate biopsies in a
population aged 60–79 years [7].
AsecondPSAderivatethat isregularlyusedisPSA
density. When a cut-off value of 0.078 is used for PSA
density, the sensitivity for detection of prostate cancer
is95%[5].EspeciallyinintermediatePSAlevels,PSA
density nomograms allow a more precise determina-
tion than age-related PSA levels [8].
A third very frequently used PSA derivative, which
is related to PSA kinetics, is PSA velocity. Despite its
frequent use, caution is required as different methods
exist to calculate PSA velocity [9]. The best way to
calculate PSA velocity is by performing linear regres-
sion. However, in routine practice urologists often use
the rate of PSA change using the ﬁrst and last value.
The arithmetic equation of PSA change should not be
recommended[9].Carter[10]proposedacut-offvalue
of0.75 ng ml
-1year
-1forPSAvelocity.Since theuse
ofthiscut-offvaluehasbeenshowntoresultinmissing
48% of prostate cancers, Loeb [11] advised in men
younger than 60 years to use a cut-off value of
0.4 ng ml
-1year
-1. Additionally, Berger [12] showed
that PSA velocity increases in the years before
diagnosis of prostate cancer, which correlates well
with the pathological stage and with Gleason scores.
Another PSA derivate that can be used is the PSA
ratio. The use of this parameter with a cut-off value of
25% results in sensitivity of 95% in prostate cancer
diagnosis[5].Catalona[13]provedthattheuseofPSA
ratio can reduce the number of unnecessarily per-
formedbiopsiesinmenwithelevatedPSAlevelsonthe
condition that cut-off values are well deﬁned. An
additionalPSA-derived parameterwasinvestigated by
Froehner who evaluated the value of complexed PSA
in comparison with total PSA [14]. Using this param-
eter, a statistical advantage was detected. However,
clinical relevance remains unclear.
Several authors investigated the use of ‘‘benign’’
PSA [15–18]. BPSA is a ‘‘benign’’ form of free PSA
that seems to be increased in patients with BPH. A
correlation was found with transition zone volume
and total prostate volume. However, as is the case
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123with some other PSA derivatives, more studies are
needed to conﬁrm its clinical utility.
In addition to these PSA-derived parameters,
molecular assays are a new tool that can be used to
reﬁne difﬁculties in PSA interpretation. A well-
described and commercially available molecular
assay is the PCA3 assay [19]. PCA3 is a very
prostate cancer-speciﬁc gene also called DD3. When
a cut-off value of 35 is used, sensitivity amounted
58–65% with a speciﬁcity of 66–72% (PSA speciﬁc-
ity of 47%) [19–21]. Haese and colleagues [22]
conducted a prospective, multicentre study including
463 patients with one or two negative biopsies who
were scheduled for a repeat biopsy. Aim of the study
was to compare the diagnostic accuracy of PCA3
with fPSA%. With a cut-off value of 35 for PCA3,
the probability of a positive repeat biopsy was greater
if PCA3 was higher. Deras et al. [23] found PCA3 to
be independent of prostate volume, serum PSA, and
number of previous biopsies. Although these assays
are promising, there are some disadvantages related
to these tests. First of all, it should be emphasised that
they cannot be used in a routine screening as they are
far more expensive. Secondly, these tests can also
give false-negative and false-positive results. There-
fore, more evidence conﬁrming the use and the
outcome of these assays is required. Last but not
least, in addition to these molecular assays, common
extended prostate biopsies are still needed to prove
possible prostate cancer.
Strategies related to technique and prostate biopsy
regimen
Numerous publications have been made on tech-
niques of prostate biopsies. Hodge [24] started with
ultrasound guided, 6-core random biopsies. Subse-
quently, Eskew [25] proved 5-region prostate biop-
sies to be superior to sextant biopsies, resulting in an
increasing diagnostic yield. A few years later, a 10-
core protocol with laterally directed biopsies together
with sextant biopsies was developed by Gore [26].
Arnold [27] extended the biopsy technique to a 12-
core regimen. This extension resulted in a 13.5%
increased detection rate of prostate cancer in com-
parison with sextant biopsies combined with transi-
tion zone biopsies [28]. Additional techniques were
developed by Matsumoto [29], who described a
technique where special attention was taken for deep
apical biopsies and Lui [30], who advised on more
speciﬁc attention for transition zone biopsies. How-
ever, other authors have shown that biopsies of
transition zone and seminal vesicles resulted in low
additional yield in the diagnosis of prostate cancer
[31–33]. Recently, Guichard [34] proposed a 21-core
biopsy protocol. Compared to sextant biopsies, a 22%
improvement in prostate cancer detection rate was
observed with a 12-core biopsy. When using a 21-
core protocol, the cancer detection rate was further
increased to 42.5% compared to 38.7% with 12-core
biopsies. Scattoni et al. [35] reviewed the literature
on extended and saturation prostate biopsies and
concluded extended biopsies should be performed at
ﬁrst biopsy, saturation biopsies at repeated biopsies.
However, Ashley [36] evaluated the diagnostic yield
of saturation biopsies. In these latter biopsy protocols,
24 or more biopsy cores are taken. Ultimately, they
proved that saturation biopsies did not detect more
abnormal pathology than standard biopsies [36].
Although prostate biopsies are a standard tech-
nique, one has to be aware of the possible compli-
cations of this procedure, which are excellently
reviewed by Raaijmakers [37]. Minor complications
such as haematuria, hemospermia, etc. are frequently
seen. Severe complications occur less frequently:
fever (3.5%), acute urinary retention (0.4%), and
hospitalisation (0.5%).
Another dilemma with prostate biopsies is how
many repeat biopsies should be taken. Djavan [38,
39] investigated the cancer detection rate in repeat
biopsies. He observed that prostate cancer detection
rate in a ﬁrst biopsy was 24%. In a second biopsy, the
cancer detection rate lowered to 13%. Prostate
cancers found in ﬁrst and second biopsies were
comparable in terms of PSA, grade, stage, and cancer
volume. Cancer detection rate in biopsies three and
four were far less, 5 and 4% respectively.
What to do if extended prostate biopsies remain
negative and PSA keeps on rising?
In case prostate biopsies remain negative and PSA
keeps on rising at the same time, many urologists
treat these patients with antibiotics. However, several
authors noticed that inﬂammation seems to have no
effect on PSA [40–42], putting the antibiotic treat-
ment in question. Another frequently used strategy
is an attempt to normalise PSA with dietary
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123manipulation [43–45]. However, these data do not
support the hypothesis that dietary manipulation
protects against prostate cancer. For example, Eas-
tham [46] showed that fat intake was not associated
with PSA levels. Therefore, advocating functional
foods or supplements explicitly for cancer control
purposes would currently be premature.
What has been suggested so far to deal
with those patients?
Several authors [47–50] showed that PSA can be seen
as a marker for BOO, as a predictor of future prostate
growth and as a marker for risk of acute urinary
retention in patients with LUTS. Furthermore, a
correlation was found with an elevated need for
surgical treatment of BPH in symptomatic patients
[50].
However, the challenging problem are patients
with elevated and/or rising PSA, minor LUTS,
normal digital rectal examination (DRE) and/or
TRUS, and (multiple) negative extended prostate
biopsies. This problem is well recognised in literature
[51, 52].
A ﬁrst attempt to deal with this problem was
described by Rovner [53]. He showed that a trans-
urethral sampling of at least four quadrant chips
together with prostate biopsies in patients with
elevated and/or rising PSA levels and negative
prostate biopsies did not signiﬁcantly improve pros-
tate cancer diagnosis. Kitamura [54] evaluated 139
consecutive patients with negative prostate biopsies.
These patients received TURP for relief of LUTS
implying that these patients were symptomatic.
Because four of these patients were revealed to have
prostate cancer during the follow-up period, the
authors concluded that the role of TURP in these
patients remained unclear. Zigeuner [55] performed a
retrospective analysis in patients with LUTS. All
patients had (multiple) negative extended prostate
biopsies. Another important characteristic in this
group of patients was that besides an elevated PSA
level, 21.8% of these patients had an abnormal DRE.
After TURP, prostate cancer was detected in 7.9% of
all cases and in 5.5% of the patients with a normal
DRE. Zigeuner [55] concluded that detection rate was
low and that diagnostic yield in asymptomatic men
remained unknown.
O ¨zden [56] evaluated 64 patients with LUTS and
normal DRE presenting with elevated PSA levels and
negative extended prostate biopsies. When TURP
was performed, BPH was encountered in 63 patients,
and in 1 patient prostatic intraepithelial neoplasia was
detected. Six months after TURP, 7 of 64 patients
still had an elevated PSA level. In 3 of these 7
patients, prostatitis was suggested to be the reason of
PSA elevation; 1 patient seemed to have prostate
cancer; and the remaining 3 patients were diagnosed
having BPH. The long-term follow-up in these 7
patients was unclear.
Radhakrishnan [57] described a retrospective
analysis in 14 patients undergoing TURP after at
least two negative extended prostate biopsies. In 21%
of the subjects, aggressive prostate cancer was
encountered. In 50% of the subjects, PSA values
returned to normal after TURP. In 1 patient, repeated
prostate biopsies revealed prostate cancer after
TURP. Philip [58] presented results in 11 patients
with prostate cancer diagnosed in TURP after neg-
ative extended prostate biopsies with 24–48 cores.
Out of these 11 patients, 5 patients underwent a
radical retropubic prostatectomy in which organ-
conﬁned cancer was found, especially located ante-
riorly. Additionally, in this group of patients TURP
was performed to resolve LUTS. Important to notice
in this group of patients is that prostate cancer was
mainly located anteriorly.
Puppo [59] described the role of TURP together
with biopsies of the peripheral zone in the same
session in the diagnosis of prostate cancer after
repeated negative biopsies. In this study, a group of
43 patients with at least two negative extended
prostate biopsies is described. In 35 of the 43
patients, further PSA elevation was shown and these
patients underwent new prostate biopsies. In 7 of 35
patients, prostate cancer was shown after repeated
prostate biopsies. Additionally, 3 patients were lost
during the follow-up period and 4 patients had a
severe co-morbidity and hence were unable to
undergo TURP. The remaining 21 patients were
offered TURP together with prostate biopsies of the
peripheral zone regardless of BOO. In this group of
21 patients, 14 patients accepted to undergo TURP. In
8 of these 14 patients, prostate cancer was diagnosed
and these patients underwent a radical prostatectomy.
The remaining 6 patients had no cancer in TURP
specimen and were followed with a median follow-up
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123of 9 months. Persistently rising PSA values were
noted for 2 of these 6 patients. However, on repeated
prostate biopsies, no signs of prostate cancer were
detected. Puppo [59] concluded that TURP together
with lateral extended prostate biopsies had a high
diagnostic power in patients with previously negative
extended prostate biopsies and rising PSA levels.
Several authors investigated the value of new
imaging techniques that can possibly be used for
targeted biopsies. A ﬁrst new emerging and promis-
ing technique is contrast-enhanced ultrasound of the
prostate (CEUS). This technique overcomes classical
limitations of conventional ultrasonography in the B-
mode imaging of parenchymal disease. With CEUS,
the blood ﬂow in the prostate can be investigated
which will result in a better detection of abnormal
micro- and macro-vascular lesions. Applying CEUS
targeted biopsies, more cancers can be detected in
comparison with systematic ultrasound guided biop-
sies [60–62]. In a multicentre European study, this
technique was further evaluated [63]. Cancer was
visualised and localised in 78%. However, further
studies to conﬁrm these results have to be initiated.
Other authors performed research on real time
elastography (RTE). With this technique, tissue
stiffness is investigated as this is related to cancer
high cell density. Additionally, RTE can be used for
targeted biopsies. However, also for this technique
further studies are needed to approve the value in
prostate cancer imaging and targeted biopsies [64–
68]. Another innovative technique in prostate cancer
imaging and targeted biopsies is magnetic resonance
(MR) and MR-guided biopsies of the prostate. This
technique is well discussed in a recent review by
Pondman et al. [69]. However, this technique also
needs further evaluation.
In our series of studies [4, 70–72], we included a
population with very speciﬁc characteristics that are
notwithstanding regularly encountered in a urological
practice. Therefore, we investigated patients with
elevated and/or rising PSA, minor LUTS, negative
DRE and TRUS, and (multiple) negative extended
prostate biopsies. In this group of patients, we found
that BOO is extremely likely to occur [4]. In a
retrospective analysis of 82 patients [71], 74 patients
were shown to suffer from BPH after TURP. In these
74 patients, only 3 patients (4.1%) had an equivocal
PdetQmax (detrusor pressure at maximum ﬂow)
according to Abram–Grifﬁths [3], while nearly all
patients (95.9%) were clearly obstructed with a mean
PdetQmax of 89.5 cm H2O (range 20–200 cm H2O).
In a prospective group of 33 patients, mean PdetQmax
was 80.3 cm H2O (range 40–150 cm H2O) [72].
When TURP was performed in patients with these
characteristics, this resulted in a symptomatic beneﬁt
(international prostate symptoms score [IPSS]/quality
of life) and (super)normalisation of PSA levels both
in our retrospective and prospective study [71, 72].
Most of the patients seemed to have BPH (retrospec-
tive study: 74/82 = 90.2%; prospective study: 27/
33 = 81.8%). However, a few subjects suffered
aggressive prostate cancer (taking into account the
age of the subject, the Gleason score, and the amount
of cancer cells) that needed further treatment [73, 74].
This was the case in 7 of 8 non-BPH patients in the
retrospective analysis (n = 82) [71] and in 2 of 6
non-BPH patients in our prospective analysis
(n = 33) [72]. On the other hand, in 1 of 8 non-
BPH patients (n = 82) [71] and in 4 of 6 (n = 33)
non-BPH patients [72], unaggressive prostate cancer
was found. For these patients, watchful waiting was
proposed. These results were conﬁrmed in a long-
term follow-up analysis with a mean follow-up of
61.5 months. In the same analysis, we found 1 patient
(out of 36) who had a persistently rising PSA that
resulted in positive extended prostate biopsies 4 years
after TURP. This patient received further treatment
with radical retropubic prostatectomy and has a
tumour-free follow-up of 36 months [71].
As already mentioned, in our series of studies,
most patients proved to have BPH after TURP
(90.2% retrospective series; 81.8% in prospective
series; 93.9% in prospective series with no aggressive
cancer, only small amount of cancer cells or BPH).
This implies that in this particular group of patients,
even PCA3 testing, saturation prostate, biopsies,
CEUS, RTE, and MR-guided biopsies will remain
negative, since there is no cancer to be found. When
in this group of patients’ PSA remains elevated or
even rises, confusion will increase and patients
cannot be submitted for ever to high-tech, cumber-
some, expensive new investigations such as PCA3,
CEUS, RTE, or MR. Additionally, it should also be
emphasised that even new technologies have false-
positive and false-negative result. Last but not least,
most of these new investigations have to be inves-
tigated more thoroughly in the future. Considering
these remarks, no clear answer will be found in this
Int Urol Nephrol (2010) 42:29–38 33
123group of patients explaining the elevated and/or
rising PSA levels. Moreover, it should be emphasised
that we found in our series that in patients who
underwent a radical prostatectomy, cancer was
mainly located anteriorly in the peripheral zone,
which is not easily accessible for prostate biopsies
regardless of the targeting technique.
Proposal of a new algorithm in patients with
elevated and/or rising PSA, minor LUTS, normal
DRE and/or TRUS, and (multiple) negative
extended prostate biopsies
Patients showing abnormal screening parameters, but
with a negative cancer screening result, can be
terriﬁed because there is no answer for their abnormal
values [75–77]. For example, Katz [51] showed that
men with abnormal values observed during prostate
cancer screening, have an increased cancer-related
worry and show more problems with sexual function
despite their negative biopsy results. Furthermore, we
know that medical treatment has no effect on PSA
levels (in case of a1 blockers) or a heterogeneous
effect on PSA levels (in case of 5a reductase
inhibitors) [78, 79]. Concerning 5a reductase
inhibitors, Brawer [78] showed ‘‘the multiply by
two rule’’ is not correct.
We also know that if BOO is not treated, patients
are at increased risk of detrusor decompensation and/
or renal insufﬁciency [80, 81]. Taking into account
the economic aspects of the different treatments for
BPH [82–84] and knowing that TURP should no
longer be seen as an invasive treatment [85–89],
offering TURP to these patients can be a valuable
alternative strategy after BOO was proven with
urodynamic evaluation, since pressure-ﬂow studies
can exclude patients who will not beneﬁt from TURP.
Moreover, the pressure-ﬂow studies provide great
predictive value of clinical improvement after TURP.
The worse the degree of BOO, the higher the efﬁcacy
of TURP seemed to be [90–93]. Therefore, we
suggest that in these patients with elevated and/or
rising PSA level, and/or abnormal PSA velocity, and/
or abnormal PSA density, and/or abnormal PSA ratio
together with minor LUTS and negative DRE and
TRUS, extended prostate biopsies should be taken
with at least 12 cores (Fig. 1). Special attention
should be taken for lateral and anterior peripheral
biopsies as well as transition zone biopsies. If patients
suffer from mild LUTS (IPSS 0–7), at least one series
of repeated extended prostate biopsy should be taken
Fig. 1 Algorithm in
patients with elevated and/
or rising PSA, minor LUTS,
normal DRE and/or TRUS,
and (multiple) negative
extended prostate biopsies.
PSA prostate-speciﬁc
antigen, DRE digital rectal
examination, TRUS
transrectal ultrasound,
LUTS lower urinary tract
symptoms, EPB extended
prostate biopsies, IPSS
international prostate
symptoms score, UDO
urodynamic observations,
PdetQmax detrusor pressure
at maximum ﬂow, TURP
transurethral resection of
prostate, BPH benign
prostatic hyperplasia
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123(Fig. 1). In patients with moderate LUTS (IPSS 8–
19), one well-performed extended prostate biopsy
should be sufﬁcient (P = 0.012, [76]). If extended
prostate biopsies remain negative, patients should be
offered an urodynamic examination with pressure-
ﬂow analysis (Fig. 1). One can expect these patients
to have an obstructive pressure-ﬂow value (or at least
equivocal). In that case, TURP can be discussed and
proposed (Fig. 1). Performing TURP, special atten-
tion should be given to the anterior prostate zone.
Conclusion
Patientswithelevatedand/orrisingPSA,minorLUTS,
normal DRE and/or TRUS, and (multiple) negative
extended prostate biopsies are a conundrum. We
showed that in these patients, urodynamics with
pressure ﬂowmetry should be performed since BOO
can be expected. In this population, we proposed a
‘‘diagnostic’’ TURP with special attention for the
anterior prostate. This will probably result in a
(super)normalisation of PSA levels and symptomatic
beneﬁt, suggesting that BOO, even with minor LUTS,
can be seen as a discomfort for patients. However,
histological examination will reveal prostate cancer in
few cases. This prostate cancer might be aggressive
needing further treatment.
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